Takeda Completes New Manufacturing Facilities in Germany

Investment and Timeline

Takeda has completed the construction of new manufacturing facilities at its Oranienburg site in Germany, with a total investment of around 100 million euros. The facility is scheduled to begin operations by the end of 2017. The state of Brandenburg and the German federal government each contributed half of the approximately 23 million euros in subsidies for the plant expansion.

Key Figures and Attendance

The importance of this investment was highlighted by the attendance of notable figures at the inauguration ceremonies, including the Federal Chancellor of Germany, Angela Merkel, Japan's Ambassador to Germany, Takeshi Yagi, the Federal State Prime Minister of Brandenburg, Dietmar Woidke, and Takeda’s President and CEO, Christophe Weber.

Global Network Optimization

As part of Takeda's initiative to optimize its global network, the manufacture of solid dosage form pharmaceutical products will be transferred from the Osaka Plant to the Oranienburg Plant and the Hikari Plant. The Oranienburg site, with its 130-year history of pharmaceutical production, plays a crucial role in Takeda’s global manufacturing network.

Production and Employment

Specialized in producing solid forms such as pills and capsules, the Oranienburg site manufactures and supplies many of Takeda’s drug products to 100 countries worldwide. These include drugs for gastroenterology (e.g., Pantoprazole), central nervous system (e.g., Trintellix), and cardiovascular system (e.g., Magnyl). The expanded production capacity will meet the increased demand in global markets, including rapidly growing emerging markets, and has already created about 180 new jobs.